Denali Therapeutics (DNLI) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.68
- Estimate
- -$0.52
- Surprise
- -29.9%
- Revenue (period 2026-06-30)
- $3.6M
- Score today
- 5.6/10
Revenue source: mixed.
How the report landed
Denali Therapeutics (DNLI) reported a wider loss than forecast — adjusted EPS of -$0.68 against the -$0.52 estimate (a 29.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates DNLI Sell at 5.6/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -29.9% surprise compares with a -9.7% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: tividenofusp alfa
- Quality below floor (1.8 < 4.0)
- EARNINGS_PROXIMITY:5d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.63
- Price target
- $31.95
- Stop
- $18.25
- Upside to target
- +62.8%
- Reward-to-risk
- 5.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
DNLI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.08B
- P/E (fwd)
- -8.0
- 52-week range
- $13.75–$27.30
- Off 52-week high
- 28.1%
- RSI (14)
- 51
- Volume vs avg
- 0.02×
- Score today
- 5.6/10